Sabby Management LLC Has Boosted Holding in Esperion Therapeutics INC (ESPR)

April 24, 2018 - By Hazel Jackson

Investors sentiment decreased to 1.33 in Q4 2017. Its down 0.34, from 1.67 in 2017Q3. It dropped, as 19 investors sold ESPR shares while 39 reduced holdings. 33 funds opened positions while 44 raised stakes. 22.69 million shares or 0.18% less from 22.73 million shares in 2017Q3 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 1,168 shares. Moreover, Stifel Financial Corporation has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 10,659 shares. 70 are held by North Star Corp. State Of Wisconsin Invest Board owns 11,000 shares or 0% of their US portfolio. Parallax Volatility Advisers Lp accumulated 2,562 shares or 0% of the stock. Toth Advisory has invested 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). 29,555 were reported by Employees Retirement Of Ohio. First Mercantile Trust holds 4,233 shares. Northern Trust invested in 574,377 shares. Creative Planning owns 4,776 shares for 0% of their portfolio. National Bank Of Montreal Can holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 7,596 shares. Oakmont Partners Limited Liability Com reported 4,900 shares. Moreover, Natixis has 0.01% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Moreover, Teacher Retirement Systems Of Texas has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). American Intl Group Inc Incorporated, New York-based fund reported 11,430 shares.

Hal Mintz increased its stake in Esperion Therapeutics Inc (ESPR) by 70.57% based on its latest 2017Q4 regulatory filing with the SEC. Sabby Management Llc bought 58,828 shares as the company’s stock rose 22.41% while stock markets declined. The hedge fund run by Hal Mintz held 142,185 shares of the health care company at the end of 2017Q4, valued at $9.36 million, up from 83,357 at the end of the previous reported quarter. Sabby Management Llc who had been investing in Esperion Therapeutics Inc for a number of months, seems to be bullish on the $1.95B market cap company. The stock decreased 0.33% or $0.24 during the last trading session, reaching $73.03. About 95,352 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since April 24, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Sabby Management Llc, which manages about $835.79 million and $1.08B US Long portfolio, decreased its stake in Bristol Myers Squibb Co (NYSE:BMY) by 51,148 shares to 931,807 shares, valued at $57.10 million in 2017Q4, according to the filing. It also reduced its holding in Amarin Corporation Plc (Call) by 10,232 shares in the quarter, leaving it with 2,418 shares, and cut its stake in Alnylam Pharmaceuticals Inc (Call).

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 11 analysts covering Esperion (NASDAQ:ESPR), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Esperion had 16 analyst reports since November 22, 2017 according to SRatingsIntel. The company was maintained on Wednesday, February 21 by UBS. On Monday, January 15 the stock rating was maintained by Stifel Nicolaus with “Buy”. Citigroup downgraded the stock to “Hold” rating in Monday, January 22 report. Chardan Capital Markets maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Tuesday, March 27. Chardan Capital Markets has “Neutral” rating and $100 target. The firm has “Buy” rating by Needham given on Wednesday, February 21. Northland Capital maintained the stock with “Buy” rating in Wednesday, November 22 report. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Thursday, December 14 by Needham. The rating was maintained by JP Morgan on Wednesday, February 21 with “Neutral”. On Wednesday, March 7 the stock rating was maintained by Cowen & Co with “Buy”. Northland Capital maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Thursday, April 19 with “Buy” rating.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.